Eli Lilly and Company has entered its seventh strategic collaboration with Innovent Biologics to develop new oncology and immunology therapies. This agreement deepens a long-standing partnership focused on accelerating Innovent’s innovative pipeline for global markets.
Innovent will lead program development from initial concept through the completion of Phase 2 clinical trials in China. Eli Lilly holds the exclusive license to further develop and commercialize these potential medicines in all markets outside of Greater China.
Innovent retains all development and commercialization rights within Greater China. The collaboration structure combines Innovent’s agile early-stage discovery with Eli Lilly’s extensive global scale.